Number of shares and votes in Orexo

Uppsala, Sweden – October 31, 2016 – The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company’s incentive programs and, as previous announced, by issue and repurchase of class C shares.

Today, the last trading day of the month, there are in total 34,870,326 shares - whereof 34,535,326 are ordinary shares and 335,000 class C shares - and 34,568,826 votes in the company.

For further information, please contact:

Orexo AB (publ.)

Henrik Juuel, EVP and CFO Lena Wange, IR   & Communications Manager
Tel: 018 780 88 00 Tel: 018 780 88 00
email: ir@orexo.com email: ir@orexo.com

About Orexo

Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in Uppsala, Sweden.

For more information about Orexo, please visit www.orexo.com or follow us on Twitter or LinkedIn. For further information about Zubsolv in the US, please visit www.zubsolv.com.

The information was submitted for publication at 6:00pm CET, October 31, 2016

Tags:

About Us

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies.The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.

Subscribe

Documents & Links